Noriko Uchiyama
Takeda (Japan)(JP)
Publications by Year
Research Areas
Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Microtubule and mitosis dynamics, Cancer-related Molecular Pathways, Vascular Tumors and Angiosarcomas
Most-Cited Works
- → CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor(2017)136 cited
- → 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole Derivatives as Novel Inhibitors of Glycogen Synthase Kinase-3β with Good Brain Permeability(2009)123 cited
- → Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives(2013)112 cited
- → Design, synthesis and structure–activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β(2009)106 cited
- → Reciprocal Roles for CCAAT/Enhancer Binding Protein (C/EBP) and PU.1 Transcription Factors in Langerhans Cell Commitment(2002)106 cited
- → A novel glycogen synthase kinase‐3 inhibitor 2‐methyl‐5‐(3‐{4‐[(S )‐methylsulfinyl]phenyl}‐1‐benzofuran‐5‐yl)‐1,3,4‐oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer’s disease(2011)89 cited
- → TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens(2011)77 cited
- → Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor(2019)67 cited
- → Discovery of 3-Benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors(2018)61 cited
- → Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)(2013)48 cited